|
|
|
|
|
24.06.25 - 13:06
|
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion (GlobeNewswire EN)
|
|
|
NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a $2 billion funding arrangement with Revolution Medicines, consisting of a synthetic royalty of up to $1.25 billion on daraxonrasib and a senior secured loan of up to $750 million. These funds will support Revolution Medicines' plans for global development and commercialization of daraxonrasib and its pipeline programs for patients with RAS-addicted cancers....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14.05.25 - 14:03
|
Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer (GlobeNewswire EN)
|
|
|
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient has been dosed in RASolve 301, a global, randomized, open-label Phase 3 clinical trial. RASolve 301 will evaluate the safety and efficacy of daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor, in patients with previously treated, locally advanced or metastatic RAS mutant non-small cell lung cancer (NSCLC) compared to docetaxel chemotherapy....
|
|
|
|
|
|
|
|
|
|
|
30.04.25 - 22:09
|
Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025 (GlobeNewswire EN)
|
|
|
REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter of 2025 on Wednesday, May 7, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
